CompanyCMNDNasdaqVancouver, British Columbia, Z4

Clearmind Medicine Inc.

Clearmind Medicine is a clinical-stage biotech company developing non-hallucinogenic, neuroplastogen-derived therapeutics for alcohol use disorder and other neurological conditions.

Stories only

SEC EDGAR ClinicalTrials.gov clearmindmedicine.com

6-KSep 30Latest SEC filing

Sep 24Latest story

September 2026

Clearmind gets Yale IRB clearance to expand CMND-100 trial recruitment

Sep 8Regulatory decisionClearmind Medicine Inc.

Clearmind Medicine agrees to acquire 51% stake in Israeli wireless EV charging firm

Sep 4M&AClearmind Medicine Inc.

Clearmind starts Phase IIa dosing in alcohol use disorder trial, six patients enrolled

Sep 1Clinical readoutClearmind Medicine Inc.

August 2026

Clearmind's DSMB clears Phase I/II AUD trial to advance to next stages

Aug 6Regulatory decisionClearmind Medicine Inc.

Clearmind Medicine signs LOI to acquire 51% stake in EV wireless charging firm

Aug 3M&AClearmind Medicine Inc.

July 2026

Clearmind reports investigator update on CMND-100 trial for alcohol use disorder

Jul 13Clinical readoutClearmind Medicine Inc.